Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer

Fineline Cube May 9, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Fineline Cube May 9, 2026
Company Deals

Gaoling Medical Secures Funding for Infrared Thermotherapy Technology

Fineline Cube Jan 11, 2023

Gaoling Medical, a Hangzhou-based developer of systemic infrared thermotherapy technology, has raised an undisclosed amount...

Company Drug

Yiling Pharmaceutical’s BIO-008 Accepted for Review by China’s NMPA

Fineline Cube Jan 11, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that its clinical trial filing for...

Company Deals

Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China

Fineline Cube Jan 11, 2023

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has...

Company Deals

CanSino Biologics to Issue GDRs on SWX Swiss Exchange to Boost Globalization

Fineline Cube Jan 11, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced plans to issue an undisclosed amount...

Company Drug

Luye Pharma Launches Named Patient Program for Lurbinectedin in Hong Kong

Fineline Cube Jan 11, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the launch of a Named Patient Program...

Company Drug

Innovent Biologics Doses First Patient in Phase III Study for Mazdutide

Fineline Cube Jan 10, 2023

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the first patient has been dosed...

Policy / Regulatory

China Meheco Keyi Pharma’s Ganciclovir Loses VBP Bid After Inspection Failure

Fineline Cube Jan 10, 2023

The national drug alliance procurement office has released a notification indicating that China Meheco Keyi...

Policy / Regulatory

NMPA Releases 63rd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has released the 63rd batch of reference drugs for...

Company Drug

Cosunter’s COVID-19 Drug GST-HG171 Shows Superior Efficacy in Trial

Fineline Cube Jan 10, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced positive results from an investigator-initiated...

Company Drug

Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China

Fineline Cube Jan 10, 2023

The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...

Policy / Regulatory

NMPA Approves Expanded Production for COVID-19 Symptom Treatments

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has approved filings from multiple companies to expand manufacturing...

Company Drug

Roche’s Glofitamab and Dizal’s Sunvozertinib Enter Priority Review

Fineline Cube Jan 10, 2023

The Center for Drug Evaluation (CDE) website indicates that Swiss giant Roche’s (SWX: ROG) glofitamab...

Company Deals

Yinjia Biosciences Raises RMB 100 Million in Series A Financing Round

Fineline Cube Jan 10, 2023

Yinjia Biosciences, a Shanghai-based developer of protein reagents and diagnostic products, has reportedly raised close...

Policy / Regulatory

China Optimizes Medical Insurance Policies for COVID-19 Treatment

Fineline Cube Jan 10, 2023

The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center...

Company Deals

China Resources Biopharmaceutical Secures RMB 600 Million in Series B Funding

Fineline Cube Jan 10, 2023

China Resources Biopharmaceutical Co., Ltd has announced the completion of a Series B financing round,...

Company Drug

Adagene’s ADG126 Shows Promise in Combination with Anti-PD-1 Therapy

Fineline Cube Jan 10, 2023

China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...

Company

Pfizer CEO Denies Licensing Paxlovid to Chinese Generics Firms

Fineline Cube Jan 10, 2023

Pfizer Inc. (NYSE: PFE) CEO Albert Bourla, speaking on the sidelines of the JPMorgan Healthcare...

Company

Legend Biotech Receives Nasdaq Notice Regarding Listing Compliance

Fineline Cube Jan 10, 2023

Legend Biotech Corporation (NASDAQ: LEGN) announced on January 6, 2023, that it received a notice...

Company Drug

Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study

Fineline Cube Jan 9, 2023

China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration...

Company Drug Policy / Regulatory

Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute

Fineline Cube Jan 9, 2023

The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...

Posts pagination

1 … 572 573 574 … 662

Recent updates

  • Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
  • Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors
  • Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
  • Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer

Company

Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for KRAS G12D Inhibitor HRS-6093 and Multiple Combination Regimens in Advanced Solid Tumors

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.